Media

Media contact

Media library

Fast facts

Page last modified 01 October 2018

You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.

Choose region and then country

Other Lundbeck sites

Global contacts

Media

Welcome to the media section

Latest releases

Lundbeck increases its share capital by 6,574 shares (0.0033 % of outstanding shares) as a result of exercise of employee warrants

Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised

Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia

U.S. Food and Drug Administration approves expansion of Trintellix® (vortioxetine) label

Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine in Japan for the treatment of Major Depressive Disorder (MDD)

Media contact

General press enquiries, please call +45 3643 4000

Media library

Access visual aids for stories about Lundbeck

Fast facts

Get a quick overview of Lundbeck and our business